Cytomorphologic findings of low-grade fibromyxoid sarcoma.


Journal

Journal of the American Society of Cytopathology
ISSN: 2213-2945
Titre abrégé: J Am Soc Cytopathol
Pays: United States
ID NLM: 101613234

Informations de publication

Date de publication:
Historique:
received: 30 12 2019
revised: 29 01 2020
accepted: 31 01 2020
pubmed: 22 3 2020
medline: 29 6 2021
entrez: 22 3 2020
Statut: ppublish

Résumé

Low-grade fibromyxoid sarcoma (LGFMS) is a rare fibroblastic tumor characterized by a prolonged clinical course and malignant biological behavior. Given its deceptively bland cytomorphology, a diagnosis can be quite challenging notably on fine-needle aspiration (FNA). In an attempt to shed light on some of the distinctive cytomorphologic characteristics, this study was conducted to review all cases of LGFMS in our database, correlating available clinical data, immunohistochemical findings, and molecular analysis. This series included 20 FNAs from 18 patients with a histologically confirmed LGFMS diagnosis from 3 large academic institutions. Detailed cytomorphologic analysis for each case was documented in conjunction with corresponding clinical characteristics and provided ancillary testing. Out of 14 adequate FNA samples, 9 (64.2%) demonstrated a mixture of fibrous and myxoid pattern; the majority of cases were composed of deceptively bland tumor cells with rare nuclear pleomorphism and nuclear membrane irregularities. A MUC4 immunostain was performed on 5 specimens; all tested positive (100%). FUS rearrangement was detected in 4 out of 5 cases (80%). Follow-up information revealed 5-year recurrence in 1 case and metastatic disease in 2 cases, to the lung/pleura (8 years) and fourth rib (1 year), respectively. The presence of bland spindle cells and associated with myxoid matrix material, in the appropriate clinical setting, can suggest LGFMS and direct additional confirmatory testing. A definitive diagnosis of LGFMS on FNA requires adequate sampling, familiarity with key cytomorphologic features, acquisition of diagnostic material for a cell block preparation and ancillary testing, and clinicoradiologic correlation.

Identifiants

pubmed: 32197967
pii: S2213-2945(20)30033-8
doi: 10.1016/j.jasc.2020.01.006
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
MUC4 protein, human 0
Mucin-4 0
RNA-Binding Protein FUS 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-201

Informations de copyright

Copyright © 2020 American Society of Cytopathology. Published by Elsevier Inc. All rights reserved.

Auteurs

Sara Mustafa (S)

Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.

Christopher J VandenBussche (CJ)

Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland. Electronic address: cjvand@jhmi.edu.

Syed Z Ali (SZ)

Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland.

Momin T Siddiqui (MT)

Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, New York.

Paul E Wakely (PE)

Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, Ohio.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH